XML 33 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies Summary of Significant Accounting Principles (Tables)
 3 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedule of Other Nonoperating Income (Expense)
The following table summarizes the components of other (expense) income, net.
 Three Months Ended September 30,
20252024
Gains (losses) on derivatives not designated as hedging instruments (1)
$3,451 $(20,569)
Currency-related (losses) gains, net (2)
(181)8,667 
Other gains
183 410 
Total other income (expense), net
$3,453 $(11,492)
_____________________
(1) Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized losses of $2,692 and $2,232 for the three months ended September 30, 2025 and 2024, respectively. Refer to Note 4 for additional details relating to our derivative contracts.
(2) Currency-related (losses) gains, net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility.
Schedule of Weighted Average Number of Shares
The following table sets forth the reconciliation of the weighted-average number of ordinary shares.
 Three Months Ended September 30,
 20252024
Weighted-average shares outstanding, basic
24,574,455 25,167,845 
Weighted-average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1)(2)
477,287 — 
Shares used in computing diluted net income (loss) per share attributable to Cimpress plc25,051,742 25,167,845 
Weighted-average anti-dilutive shares excluded from diluted net income (loss) per share attributable to Cimpress plc (1)(2)
1,955,243 1,224,628 
__________________
(1) In the periods in which a net loss is recognized, the impact of share options, PSUs, RSUs and warrants is excluded from shares used in computed diluted net loss per share as it is anti-dilutive.
(2) On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted-average shares outstanding. For the three months ended September 30, 2025, the average share price was below the strike price for the quarter; therefore, the total outstanding warrants of 1,055,377 were considered anti-dilutive. For the three months ended September 30, 2024, the average market price of our ordinary shares was higher than the strike price of the warrants, and the weighted-average anti-dilutive effect of the warrants (anti-dilutive due to our net loss position) was 341,158.